Navigation Links
Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
Date:7/18/2011

using the comparator, mesalamine delayed-release 1.6 g/day (n=336) administered as 0.8 g given twice daily (81.5%, 95% confidence interval for difference: -3.9%, 8.1%).

Safety of Lialda in the maintenance of remission of ulcerative colitis was evaluated in three studies, one being a six-month, double-blind, non-inferiority, comparator study and two being 12- to 14-month open-label studies. The most common adverse reactions with Lialda in the maintenance arms of these three trials were ulcerative colitis, headache, abnormal liver function test and abdominal pain. The most common severe adverse reactions were gastrointestinal disorders, most of which are consistent with symptoms associated with ulcerative colitis.

In 2007, Lialda gained FDA approval for the induction of remission in patients with active, mild to moderate ulcerative colitis as a result of two eight-week, placebo-controlled clinical studies demonstrating safety and effectiveness.

Important Safety InformationYou should not take Lialda if you are allergic to salicylates (including mesalamine, aspirin, or aspirin-containing products) or to any of the ingredients of Lialda.  

Reports of problems with kidney function have been associated with mesalamine-containing products like Lialda. Tell your doctor if you have or have had problems with your kidneys. It is recommended that all patients have their kidney function checked before starting Lialda and periodically while on therapy.

Products that contain mesalamine, like Lialda, have been associated with a condition that may be difficult to distinguish from an ulcerative colitis flare-up. Symptoms include cramping, stomach ache, bloody diarrhea, fever, headache, and rash. If you experience any of these symptoms, talk to your doctor immediately. Your doctor may decide to discontinue your medication.  

Tell your doctor if you are allergic to sulfasalazine, as you may also be allergic to Lialda or drugs that
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
2. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
5. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
6. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
7. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
10. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
11. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. ... SNY ; EURONEXT: SAN) and the life sciences ... to improve care and outcomes for people with type ... in diabetes treatments and devices with Google,s expertise in ... companies will explore how to improve diabetes care by ...
(Date:8/31/2015)... , Aug. 31, 2015  Asterias Biotherapeutics, Inc. ... the emerging field of regenerative medicine, today announced ... Chicago -based Rush University Medical ... activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor ... motor complete cervical spinal cord injury (SCI). This ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6
... in the New England ... and JACKSONVILLE, Fla., March 24 A study published ... Medicine suggests that intensive blood glucose (sugar) control ... does not improve outcomes and is associated with an ...
... 24 Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company ... of safety and efficacy data from the first cohort of ... recommended that Anthera,s Phase II clinical trial, known as the ... P hospholipase in A cute C hes ...
Cached Medicine Technology:Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 2Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 3Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients 4Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 2Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease 3
(Date:8/31/2015)... ... 2015 , ... When it comes to undergoing a hair transplant, most patients have donor hair ... more volume to the hair on top of the scalp, as well as filling in ... of donor hair on other areas of their head. , What about patients who have ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine Course. ... October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. The ...
(Date:8/31/2015)... ... August 31, 2015 , ... The ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation ...
(Date:8/31/2015)... ... August 31, 2015 , ... Patients who thought about ... who are interested in learning more about the procedure beyond the information found on ... Internationally recognized hair transplant surgeon Parsa Mohebi will be on hand to answer patients ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning documentary “Alive ... “Alive Inside” shadows a social worker who advocates for the use of music therapy ... bringing music to residents in health care centers who may have lost a spark ...
Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2
... Delhi government has decided to construct 36 hospitals.// ... ,"Some of these hi-tech hospitals will be built in ... the chief minister's office. ,"Initially the government had ... but more funds will be made available," the official said. ...
... HIV tests of dental patients in North Quensland. The ... a dentist working// at Bowen and Collinsville hospitals, tested ... testing of patients. Nearly 120 patients have already been ... Jeannette Young expressed that despite some patients getting ...
... during pregnancy do more harm than good according to ... study conducted by researchers revealed that babies born to ... antidepressants have more of a likelihood of having a ... is in contradiction to the belief that treating depressed ...
... the elderly has been blamed on defects in a specific gene ... estimated that about 37% of Britons from ages 61 to 70 ... people are said to have age-related hearing loss. ,The ... changes in the gene, KCNQ4 more frequent among those with age-related ...
... the High-Security Animal Disease Laboratory in Bhopal have finally helped ... against// the deadly H5N1 bird flu virus last month. However, ... to manufacture the vaccine. ,This is because there ... influenza vaccines for poultry who has a Bio Safety Level ...
... West Java province, poultry depopulation is being conducted by culling ... of// avian flu in this area. ,According to ... Rachmat said that this plan of mass culling was made ... tested positive for bird flu. ,According to Andi, ...
Cached Medicine News:Health News:Gene linked to Hearing Loss in Aged Identified 2Health News:Major Hurdle towards Development of Bird Flu Vaccine in India. 2
The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
Transcranial vascular DWL doppler....
Transcranial vascular DWL doppler....
... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
Medicine Products: